Home > Insider Trading > Filing (0001246360-14-001795)

Filing Details

Accession Number:: 0001246360-14-001795
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2014-03-14 17:07:09
Reporting Period:: 2014-03-12

Filing Date:: 2014-03-14
Accepted Time:: 2014-03-14 16:07:09
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
911326	Synageva Biopharma Corp	GEVA	Biological Products, (No Disgnostic Substances) (2836)	561808663

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1532217	Chris Heberlig	33 Hayden Ave Lexington MA 02421	Group Vice President, Finance	No	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2014-03-12	1,850	$1.70	2,042	No	4	M	Direct
Common Stock	Acquisiton	2014-03-12	820	$0.95	2,862	No	4	M	Direct
Common Stock	Acquisiton	2014-03-12	5,000	$23.00	7,862	No	4	M	Direct
Common Stock	Disposition	2014-03-12	700	$96.75	7,162	No	4	S	Direct
Common Stock	Disposition	2014-03-12	3,933	$98.49	3,229	No	4	S	Direct
Common Stock	Disposition	2014-03-12	3,037	$99.08	192	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2014-03-12	1,850	$0.00	1,850	$1.70
Common Stock	Stock Option (Right to Buy)	Disposition	2014-03-12	820	$0.00	820	$0.95
Common Stock	Stock Option (Right to Buy)	Disposition	2014-03-12	5,000	$0.00	5,000	$23.00

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
1,938	2021-05-25	No	4	M	Direct
0	2019-12-15	No	4	M	Direct
10,000	2021-12-20	No	4	M	Direct

Footnotes

The stock option exercise and sale of shares of common stock ("Shares") reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the reporting person on November 1, 2013.
The stock option granted the reporting person an option to purchase 6,188 Shares. 25% of such Shares vested and became exercisable on 05/25/2012, and 1/36 of the remainder of such Shares vest and become exercisable monthly thereafter.
The stock option granted the reporting person an option to purchase 2,820 Shares. 25% of such Shares vested and became exercisable on 09/25/2010, and 1/36 of the remainder of such Shares vest and become exercisable monthly thereafter.
The stock option granted the reporting person an option to purchase 15,000 Shares. 25% of such Shares vested and became exercisable on 12/20/2012, and 1/36 of the remainder of such Shares vest and become exercisable monthly thereafter.
This transaction was executed in multiple trades through a broker-dealer at prices ranging from $96.36 to $97.10. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
This transaction was executed in multiple trades through a broker-dealer at prices ranging from $97.77 to $98.75. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
This transaction was executed in multiple trades through a broker-dealer at prices ranging from $98.79 to $99.29. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.